Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8

Explore clinical trials studying Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8. Study availability and eligibility vary by location and protocol.

12 public trials 7 recruiting studies

Refine in advanced search Browse all conditions

Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8 trial results

Active, Not Recruiting

Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin

NCT04533750

Conditions: Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma, +34 more
Locations: Banner MD Anderson Cancer Center Gilbert, Arizona, United States

Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States

Banner University Medical Center - Tucson Tucson, Arizona, United States

University of Arizona Cancer Center-North Campus Tucson, Arizona, United States

View all 27 locations

View Trial Details

Active, Not Recruiting

A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

NCT05232851

Conditions: Carcinoma, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Neoplasms, +14 more
Locations: Mayo Clinic in Rochester Rochester, Minnesota, United States

View Trial Details

Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8

Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8 trial results

Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin

A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

Related conditions